SCHEMBL4653801

SCHEMBL4653801

CC(C)Cc1cc(CCC#N)ccc1-c1ccc(O)c(C(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.43
GABRB2 P47870 4/20 0.43
TP53 P04637 1/20 0.38
MDM2 Q00987 1/20 0.38
BCL2L1 Q07817 2/20 0.37
MCL1 Q07820 1/20 0.37
ALOX5 P09917 2/20 0.35
S1PR1 P21453 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
THRA P10827 3/20 0.32
THRB P10828 3/20 0.32
MAPK1 P28482 1/20 0.32
REN P00797 1/20 0.31
NEK1 Q96PY6 2/20 0.31
BIRC5 O15392 1/20 0.31
BACE1 P56817 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5340223 0.92 GABRA1 (0.46) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL4651628 0.89 GABRA1 (0.52) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL14066551 0.85 TP53 (0.37) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL14066557 0.84 TP53 (0.37) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL5344091 0.84 TP53 (0.41) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL4652316 0.82 TP53 (0.52) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL4651441 0.81 BCL2L1 (0.42) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL4652321 0.81 TP53 (0.54) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL4652289 0.81 TP53 (0.54) GABRA1GABRB2TP53MDM2BCL2L1
SCHEMBL5342731 0.81 GABRA1 (0.65) GABRA1GABRB2TP53ALOX5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408986-B1 PROTEOMIMETIC COMPOUNDS AND METHODS UNIV YALE (US) 2008-09-24 EP disclosed
US-7312246-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2007-12-25 US disclosed
EP-1408986-A4 PROTEOMIMETIC COMPOUNDS AND METHODS UNIV YALE (US) 2006-01-11 EP disclosed
US-20050215563-A1 Proteomimetic compounds and methods YALE UNIVERSITY 2005-09-29 US disclosed
US-6858600-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2005-02-22 US disclosed
EP-1408986-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2004-04-21 EP disclosed
US-20030008882-A1 Proteomimetic compounds and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
WO-2002089738-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008882-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 GABRA1 3941/4885GABRB2 3484/4885TP53 468/4885
US-20050215563-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 GABRA1 3941/4885GABRB2 3484/4885TP53 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.